Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Ophthalmoferon
- Development stage
- Unknown
- Lead developer
- Firn-M
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Ophthalmic
01
Overview
Ophthalmoferon is a combination ophthalmic solution developed by the Russian pharmaceutical company Firn M for the treatment of viral and allergic eye diseases. The formulation contains recombinant human interferon alfa-2b and diphenhydramine. Interferon alfa-2b acts as an agonist at the interferon alpha/beta receptor (IFNAR), inducing antiviral, immunomodulatory, and antiproliferative responses that are effective against pathogens such as adenovirus and herpes simplex virus. Diphenhydramine is a small molecule antihistamine that antagonizes the histamine H1 receptor, providing symptomatic relief from allergic inflammation, itching, and edema. Ophthalmoferon is approved and marketed in Russia and other regions for indications including viral conjunctivitis, keratitis, and allergic conjunctivitis.
- Brand names
- OphthalmoferonОфтальмоферон
- Other names
- Ophtalmoferon
02
Targets
IFNAR (Immune system modulation via type I interferon receptor)HRH1 (Histamine H1 Receptor)
Beyond the preview
Go deeper on Ophthalmoferon.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ophthalmoferon.